Table 1A.
Trials of emerging JAK inhibitors in vitiligo.
| NCT number | Sponsor | Nationality | Trial phase | Treatment group | Drug type | Subject | Allocation | Status | Results | Side effect |
|---|---|---|---|---|---|---|---|---|---|---|
| NCT04896385 | Incyte Corporation | The United States and Canada | 2 | Group1: ruxolitinib cream Group2: vehicle |
JAK1/2 inhibitor | 60 | Randomized, double-blind | Recruiting | Not available | Not available |
| NCT02809976 | Tufts Medical Center | The United States | 2 | Group 1: ruxolitinib 1.5% phosphate cream twice daily | JAK1/2 inhibitor | 11 | Single group, open-label | Completed | 4 patients presented significant facial improvement, 23% of patients decreased VASI | Only mild side effects |
| NCT03099304 | Incyte Corporation | The United Kingdom | 2 | Group 1: ruxolitinib cream 1.5% twice daily Group 2: ruxolitinib cream 1.5% once daily Group 3: ruxolitinib cream 0.5% once daily Group 4: ruxolitinib 0.15% once daily Group 5: vehicle |
JAK1/2 inhibitor | 157 | Randomized, double-blind | Completed | More patients in cream 1.5% twice daily, 1.5% once daily, 0.5% once-daily groups achieved F-VASI50 than the control groups. | Only mild side effects |
| NCT04052425 | Incyte Corporation | The United States | 3 | Group 1: ruxolitinib cream Group 2: vehicle |
JAK1/2 inhibitor | 330 | Randomized, double-blind | Active | Not available | Not available |
| NCT04057573 | Incyte Corporation | The United States | 3 | Group1: ruxolitinib cream Group 2: vehicle |
JAK1/2 inhibitor | 334 | Randomized, double-blind | Active | Not available | Not available |
| NCT04530344 | Incyte Corporation | The United States | 3 | Group 1: ruxolitinib cream Grorup2: vehicle |
JAK1/2 inhibitor | 500 | Randomized, double-blind | Recruiting | Not available | Not available |
| NCT04822584 | University Hospital, Bordeaux | France | 2 | Group 1: baricitinib Group 2: placebo |
JAK1/2 inhibitor | 48 | Randomized, double-blind | Not yet recruiting | Not available | Not available |
| NCT04103060 | Dermavant Sciences GmbH | The United States | 2 | Group 1: cerdulatinib, 0.37% gel, twice daily Group 2: vehicle gel, twice daily |
SYK and JAK inhibitor (without JAK2) | 33 | Randomized, double-blind | Completed | Not available | Not available |
| NCT03715829 | Pfizer | The United States | 2 | Group 1: PF-06651600 ritlecitinib Group 2: placebo Group 3: PF06700841 brepocitinib |
Brepocitinib: TYK2/JAK1 inhibitor Ritlecitinib: JAK3/TEC inhibitor |
366 | Randomized, double-blind | Completed | Not available | Not available |
| NCT03468855 | Aclaris Therapeutics, Inc. | The United States | 2 | Group: ATI-50002
ifidancitinib twice daily |
JAK1 and JAK3 inhibitor | 34 | Single group, open-label | Completed | Mean change in F-VASI: -0.067 (0.2411) VNS: 2.2 (0.66) |
1 Acute myocardial infarction, 1 Alcoholic Pancreatitis |
VASI, Vitiligo Area Scoring Index; F-VASI, Facial Vitiligo Area Scoring Index; VNS, Vitiligo Noticeability Scale.